Developer docs
API playgroundTry for free, no card

Search company profiles

JucaBio

Full company profile

uuid0000pbe

Namestring
JucaBio
Legal namestring
JucaBio, LLC
Websiteurl
jucabio.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

JucaBio is a privately held, clinical-stage biopharmaceutical company founded in April 2023 and headquartered in Cincinnati, Ohio. The company operates a hub-and-spoke model in which it acquires or in-licenses early-stage, differentiated therapeutics from academia, large pharma, and other biotechs — often assets that have been deprioritized or left "on the shelf" by their original sponsors — and houses each asset or asset group in a dedicated subsidiary focused on a specific disease area. JucaBio develops these candidates to a value inflection point that demonstrates utility to patients, providers, and payers, after which the portfolio company may spin out as an independent entity or be acquired by a commercial pharmaceutical or biotechnology company. Revenue is therefore expected to be event-driven, derived from licensing, milestones, royalties, or strategic acquisition proceeds rather than from product sales, and the company is currently pre-revenue.

The underlying technology competency is human drug development execution rather than a proprietary scientific platform: a fully staffed cross-functional team covering clinical operations, regulatory affairs, CMC, quality assurance, finance, and business development — almost entirely drawn from the alumni network of CinCor Pharma and CinRx Pharma. The company's most credentialed commercial outcome to date is the prior track record of its founders, Catherine Pearce and Justin Thompson, who led CinCor Pharma from formation through in-licensing of baxdrostat from Roche and ultimately through AstraZeneca's up to $1.8 billion acquisition in early 2023. That precedent, combined with CinRx's history of building six portfolio companies, is the principal operating asset JucaBio is commercializing.

As of the data captured, JucaBio operates with roughly ten employees, has not publicly disclosed named therapeutic candidates, has raised approximately $3.8 million in a January 2025 funding round, and has no disclosed subsidiaries, marketing channels, or commercial distribution. Its go-to-market is purely B2B enterprise: direct engagement with pharma and biotech business development functions for asset sourcing and, ultimately, for exits. The implication for evaluation is that JucaBio's near-term value drivers are portfolio asset acquisitions and the formation of operating subsidiaries, with monetization contingent on subsequent clinical and transactional milestones.

Short descriptiontext

JucaBio is a privately held, clinical-stage biopharmaceutical company that uses a hub-and-spoke model to acquire early-stage "shelf" therapeutics, develop them through dedicated subsidiaries to value inflection points, and exit via spin-outs or acquisitions by larger pharma and biotech companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCincinnati, United States
HQ citystring
Cincinnati
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical drug development, biopharmaceutical asset acquisition, novel therapeutics development, biotech portfolio management, early-stage drug licensing
Industry3 codes
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-Stage Biopharmaceutical Development
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Asset Development and Exit
TypeLicensing Royalties
Description

Pre-revenue company that acquires early-stage novel therapeutics and develops them through clinical stages to demonstrate value. Revenue is generated through strategic transactions including portfolio company spin-outs, acquisitions by pharma/biotech companies, or licensing deals. The company follows the hub and spoke model where each subsidiary focuses on specific assets in a disease area.

jucabio.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

JucaBio is a clinical-stage biopharmaceutical company that acquires high-quality, differentiated early-stage novel therapeutics from academia, large pharma, and biotech companies and develops them to value inflection points through agile subsidiary companies under a hub-and-spoke model. Portfolio companies are designed to spin out independently or be acquired by commercial pharma and biotech, with the leadership team's track record anchored by the up to $1.8 billion AstraZeneca acquisition of CinCor Pharma in early 2023.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • CinCor Pharma acquisition by AstraZeneca for up to $1.8 billion
Product overview1 text field

JucaBio is a privately held, clinical-stage biopharmaceutical company operating on a hub-and-spoke model. The company acquires high-quality, differentiated early-stage novel therapeutics from academia, large pharma, and other biotech companies, then builds agile subsidiaries to execute focused clinical development programs. Each subsidiary focuses on specific assets or groups of assets in a disease area, developing therapeutics to value inflection points. Portfolio companies may spin out independently or be acquired by commercial pharma and biotech companies. The company has not yet disclosed specific named products or therapeutic candidates in public-facing materials.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

JucaBio founders Catherine Pearce and Justin Thompson previously co-founded and led CinRx Pharma, LLC, which built 6 portfolio companies including CinCor Pharma. CinRx served as the parent company structure that enabled the CinCor success story, representing a proven model that JucaBio replicates.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

BridgeBio operates a hub-and-spoke structure focused on assets targeting genetic diseases and high-unmet-need indications. Its model of operating focused subsidiaries around single therapeutic programs closely mirrors JucaBio's approach and target sourcing rationale.

TypeBroad incumbent
Description

AstraZeneca acquired CinCor Pharma for up to $1.8B in early 2023, validating the founders' prior playbook. As a top-tier strategic acquirer, it represents the prototypical exit buyer for JucaBio's portfolio subsidiaries pursuing differentiated clinical assets.

TypeDirect peer
Description

Roivant is the canonical public biotech operating on a hub-and-spoke model that acquires shelved or under-resourced therapeutic assets from large pharma and develops them through clinical proof-of-concept. JucaBio applies the same asset-acquisition and subsidiary-creation playbook at a smaller scale.

TypeDirect peer
Description

PureTech Health is a clinical-stage hub-and-spoke biotherapeutics company that founded and incubated multiple subsidiaries around validated biology. Like JucaBio, it targets "shelved" or deprioritized programs and develops them to value-inflection for spin-out, licensing, or acquisition.

TypeBroad incumbent
Description

Karuna pursued a clinical-stage CNS asset (xanaceine/cobenfy) through Phase III and was acquired by Bristol-Myers Squibb for $14B in 2024. It exemplifies the "de-risk at inflection, exit to big pharma" trajectory JucaBio is building toward.

TypeRegional player
Description

Everest Medicines licenses and develops late-stage innovative therapeutics for the Asia-Pacific region, applying a hub-and-spoke platform model. It is comparable as an asset-acquisition/development entity, though its geographical focus is distinct from JucaBio's.

TypeDirect peer
Description

CinCor Pharma was the lead portfolio company of CinRx, acquired by AstraZeneca for up to $1.8B in early 2023. It represents the operating model (single-asset clinical biotech inside the hub) that each future JucaBio subsidiary is designed to emulate.

TypeDirect peer
Description

CinRx Pharma is the direct predecessor company co-founded by the same leadership team (Catherine Pearce and Justin Thompson). It pioneered the identical hub-and-spoke model, building six portfolio companies including CinCor Pharma, and serves as the structural template JucaBio replicates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

JucaBio

Clinical-Stage Biopharmaceutical Developmentjucabio.com

JucaBio is a privately held, clinical-stage biopharmaceutical company that uses a hub-and-spoke model to acquire early-stage "shelf" therapeutics, develop them through dedicated subsidiaries to value inflection points, and exit via spin-outs or acquisitions by larger pharma and biotech companies.

What JucaBio does

JucaBio is a privately held, clinical-stage biopharmaceutical company founded in April 2023 and headquartered in Cincinnati, Ohio. The company operates a hub-and-spoke model in which it acquires or in-licenses early-stage, differentiated therapeutics from academia, large pharma, and other biotechs — often assets that have been deprioritized or left "on the shelf" by their original sponsors — and houses each asset or asset group in a dedicated subsidiary focused on a specific disease area. JucaBio develops these candidates to a value inflection point that demonstrates utility to patients, providers, and payers, after which the portfolio company may spin out as an independent entity or be acquired by a commercial pharmaceutical or biotechnology company. Revenue is therefore expected to be event-driven, derived from licensing, milestones, royalties, or strategic acquisition proceeds rather than from product sales, and the company is currently pre-revenue.

The underlying technology competency is human drug development execution rather than a proprietary scientific platform: a fully staffed cross-functional team covering clinical operations, regulatory affairs, CMC, quality assurance, finance, and business development — almost entirely drawn from the alumni network of CinCor Pharma and CinRx Pharma. The company's most credentialed commercial outcome to date is the prior track record of its founders, Catherine Pearce and Justin Thompson, who led CinCor Pharma from formation through in-licensing of baxdrostat from Roche and ultimately through AstraZeneca's up to $1.8 billion acquisition in early 2023. That precedent, combined with CinRx's history of building six portfolio companies, is the principal operating asset JucaBio is commercializing.

As of the data captured, JucaBio operates with roughly ten employees, has not publicly disclosed named therapeutic candidates, has raised approximately $3.8 million in a January 2025 funding round, and has no disclosed subsidiaries, marketing channels, or commercial distribution. Its go-to-market is purely B2B enterprise: direct engagement with pharma and biotech business development functions for asset sourcing and, ultimately, for exits. The implication for evaluation is that JucaBio's near-term value drivers are portfolio asset acquisitions and the formation of operating subsidiaries, with monetization contingent on subsequent clinical and transactional milestones.

JucaBio firmographics

Firmographics
Name
JucaBio
Legal name
JucaBio, LLC
Website
https://jucabio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
JucaBio is a privately held, clinical-stage biopharmaceutical company that uses a hub-and-spoke model to acquire early-stage "shelf" therapeutics, develop them through dedicated subsidiaries to value inflection points, and exit via spin-outs or acquisitions by larger pharma and biotech companies.
Ownership category
akta.pro rank

JucaBio industry classification

Industry
Product category
Clinical-Stage Biopharmaceutical Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Clinical drug development
  • Biopharmaceutical asset acquisition
  • Novel therapeutics development
  • Biotech portfolio management
  • Early-stage drug licensing

Where JucaBio is headquartered

Location

Headquarters

HQ city
Cincinnati
HQ country
United States
HQ region
North America

Markets served

JucaBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Asset Development and Exit: Pre-revenue company that acquires early-stage novel therapeutics and develops them through clinical stages to demonstrate value. Revenue is generated through strategic transactions including portfolio company spin-outs, acquisitions by pharma/biotech companies, or licensing deals. The company follows the hub and spoke model where each subsidiary focuses on specific assets in a disease area.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

JucaBio product offering

Product offering

Core offering

JucaBio is a clinical-stage biopharmaceutical company that acquires high-quality, differentiated early-stage novel therapeutics from academia, large pharma, and biotech companies and develops them to value inflection points through agile subsidiary companies under a hub-and-spoke model. Portfolio companies are designed to spin out independently or be acquired by commercial pharma and biotech, with the leadership team's track record anchored by the up to $1.8 billion AstraZeneca acquisition of CinCor Pharma in early 2023.

Product overview

JucaBio is a privately held, clinical-stage biopharmaceutical company operating on a hub-and-spoke model. The company acquires high-quality, differentiated early-stage novel therapeutics from academia, large pharma, and other biotech companies, then builds agile subsidiaries to execute focused clinical development programs. Each subsidiary focuses on specific assets or groups of assets in a disease area, developing therapeutics to value inflection points. Portfolio companies may spin out independently or be acquired by commercial pharma and biotech companies. The company has not yet disclosed specific named products or therapeutic candidates in public-facing materials.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • CinCor Pharma acquisition by AstraZeneca for up to $1.8 billion

Companies that use JucaBio

Customer profile

Segments1 record

Ideal customer profiles2 records

JucaBio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

JucaBio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CinRx PharmacoreStrategic or Co-development PartnerJucaBio founders Catherine Pearce and Justin Thompson previously co-founded and led CinRx Pharma, LLC, which built 6 portfolio companies including CinCor Pharma. CinRx served as the parent company structure that enabled the CinCor success story, representing a proven model that JucaBio replicates.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

JucaBio competitors and assessment

Company assessment

Direct peers

  • BridgeBio Pharma: BridgeBio operates a hub-and-spoke structure focused on assets targeting genetic diseases and high-unmet-need indications. Its model of operating focused subsidiaries around single therapeutic programs closely mirrors JucaBio's approach and target sourcing rationale.
  • Roivant Sciences: Roivant is the canonical public biotech operating on a hub-and-spoke model that acquires shelved or under-resourced therapeutic assets from large pharma and develops them through clinical proof-of-concept. JucaBio applies the same asset-acquisition and subsidiary-creation playbook at a smaller scale.
  • PureTech Health: PureTech Health is a clinical-stage hub-and-spoke biotherapeutics company that founded and incubated multiple subsidiaries around validated biology. Like JucaBio, it targets "shelved" or deprioritized programs and develops them to value-inflection for spin-out, licensing, or acquisition.
  • CinCor Pharma: CinCor Pharma was the lead portfolio company of CinRx, acquired by AstraZeneca for up to $1.8B in early 2023. It represents the operating model (single-asset clinical biotech inside the hub) that each future JucaBio subsidiary is designed to emulate.
  • CinRx Pharma: CinRx Pharma is the direct predecessor company co-founded by the same leadership team (Catherine Pearce and Justin Thompson). It pioneered the identical hub-and-spoke model, building six portfolio companies including CinCor Pharma, and serves as the structural template JucaBio replicates.

Broad incumbents

  • AstraZeneca: AstraZeneca acquired CinCor Pharma for up to $1.8B in early 2023, validating the founders' prior playbook. As a top-tier strategic acquirer, it represents the prototypical exit buyer for JucaBio's portfolio subsidiaries pursuing differentiated clinical assets.
  • Karuna Therapeutics: Karuna pursued a clinical-stage CNS asset (xanaceine/cobenfy) through Phase III and was acquired by Bristol-Myers Squibb for $14B in 2024. It exemplifies the "de-risk at inflection, exit to big pharma" trajectory JucaBio is building toward.

Regional players

  • Everest Medicines: Everest Medicines licenses and develops late-stage innovative therapeutics for the Asia-Pacific region, applying a hub-and-spoke platform model. It is comparable as an asset-acquisition/development entity, though its geographical focus is distinct from JucaBio's.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

JucaBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

JucaBio leadership team

Management profile

Number of profiles

Profiles10 records

JucaBio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

JucaBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JucaBio

What does JucaBio do?

JucaBio is a clinical-stage biopharmaceutical company that acquires high-quality, differentiated early-stage novel therapeutics from academia, large pharma, and biotech companies and develops them to value inflection points through agile subsidiary companies under a hub-and-spoke model. Portfolio companies are designed to spin out independently or be acquired by commercial pharma and biotech, with the leadership team's track record anchored by the up to $1.8 billion AstraZeneca acquisition of CinCor Pharma in early 2023.

Is JucaBio a public or private company?

JucaBio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was JucaBio founded?

JucaBio was founded in 2023. It employs 11 to 50 people.

Where is JucaBio based?

JucaBio is headquartered in Cincinnati, United States, in the North America region.

How does JucaBio make money?

One revenue line is on record: asset Development and Exit.

Who are JucaBio's main competitors?

Direct peers on record are BridgeBio Pharma, Roivant Sciences, PureTech Health, CinCor Pharma and CinRx Pharma. Broad incumbents are AstraZeneca and Karuna Therapeutics. Everest Medicines is listed as a regional player.

Does JucaBio have an API?

No public API is recorded for JucaBio.

What industry is JucaBio in?

JucaBio's product category is Clinical-Stage Biopharmaceutical Development. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals